Acute Renal Failure (ARF) (Acute Kidney Injury) - Pipeline Review, H2 2016

Date: July 20, 2016
Pages: 141
Price:
US$ 2,000.00
License [?]:
Publisher: Global Markets Direct
Report type: Strategic Report
Delivery: E-mail Delivery (PDF)
ID: A6B60F3A906EN
Leaflet:

Download PDF Leaflet

Acute Renal Failure (ARF) (Acute Kidney Injury) - Pipeline Review, H2 2016

SUMMARY

Global Markets Direct’s, ‘Acute Renal Failure (ARF) (Acute Kidney Injury) - Pipeline Review, H2 2016’, provides an overview of the Acute Renal Failure (ARF) (Acute Kidney Injury) pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Acute Renal Failure (ARF) (Acute Kidney Injury), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Acute Renal Failure (ARF) (Acute Kidney Injury) and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data.

SCOPE
  • The report provides a snapshot of the global therapeutic landscape of Acute Renal Failure (ARF) (Acute Kidney Injury)
  • The report reviews pipeline therapeutics for Acute Renal Failure (ARF) (Acute Kidney Injury) by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved Acute Renal Failure (ARF) (Acute Kidney Injury) therapeutics and enlists all their major and minor projects
  • The report assesses Acute Renal Failure (ARF) (Acute Kidney Injury) therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news related to pipeline therapeutics for Acute Renal Failure (ARF) (Acute Kidney Injury)
REASONS TO BUY
  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand important and diverse types of therapeutics under development for Acute Renal Failure (ARF) (Acute Kidney Injury)
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Acute Renal Failure (ARF) (Acute Kidney Injury) pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Introduction
Global Markets Direct Report Coverage
Acute Renal Failure (ARF) (Acute Kidney Injury) Overview
Therapeutics Development
Pipeline Products for Acute Renal Failure (ARF) (Acute Kidney Injury) - Overview
Pipeline Products for Acute Renal Failure (ARF) (Acute Kidney Injury) - Comparative Analysis
Acute Renal Failure (ARF) (Acute Kidney Injury) - Therapeutics under Development by Companies
Acute Renal Failure (ARF) (Acute Kidney Injury) - Therapeutics under Investigation by Universities/Institutes
Acute Renal Failure (ARF) (Acute Kidney Injury) - Pipeline Products Glance
Late Stage Products
Clinical Stage Products
Early Stage Products
Unknown Stage Products
Acute Renal Failure (ARF) (Acute Kidney Injury) - Products under Development by Companies
Acute Renal Failure (ARF) (Acute Kidney Injury) - Products under Investigation by Universities/Institutes
Acute Renal Failure (ARF) (Acute Kidney Injury) - Companies Involved in Therapeutics Development
A1M Pharma AB
Adrenomed AG
Am-Pharma B.V.
Angion Biomedica Corp.
Atox Bio Ltd.
Cellmid Limited
Complexa, Inc.
DiaMedica Inc.
Digna Biotech, S.L.
DURECT Corporation
F. Hoffmann-La Roche Ltd.
G1 Therapeutics, Inc.
Kringle Pharma, Inc.
NephroGenex, Inc.
NeuroVive Pharmaceutical AB
Noorik Biopharmaceuticals AG
Noxxon Pharma AG
Orion Oyj
ProMetic Life Sciences Inc.
Quark Pharmaceuticals, Inc.
SBI Pharmaceuticals Co., Ltd.
Spherium Biomed S.L.
STATegics, Inc.
Stealth BioTherapeutics Inc.
Thrasos Therapeutics Inc.
Torrent Pharmaceuticals Limited
Acute Renal Failure (ARF) (Acute Kidney Injury) - Therapeutics Assessment
Assessment by Monotherapy Products
Assessment by Combination Products
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Drug Profiles
(aminolevulinic acid hydrochloride + sodium ferrous citrate) - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
A1M-001 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
AB-103 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
adrecizumab - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
BB-3 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
CAB-101 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Cardiotrophin-1 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
CXA-10 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
cyclosporine - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
DM-199 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
DUR-928 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
elamipretide - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
HYPER-IL-6 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
KP-100IT - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
levosimendan - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
MG-53 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
MIX-9 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
N-003 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
NOXD-21 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
PBI-4419 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Pyridoxamine Dihydrochloride - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
QPI-1002 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
R-190 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Recombinant Human Alkaline Phosphatase Replacement for Ulcerative Colitis, Acute Renal Failure, Sepsis and Hypophosphatasia - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Recombinant Protein for Acute Kidney Injury, Acute Radiation Syndrome, Inflammatory Bowel Disease, Ischemic Organ Injury, and Sepsis - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
RLS-003 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
RO-6839328 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecule to Inhibit CDK4 and CDK6 for Acute Kidney Injury and Breast Cancer - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecule to Inhibit HDAC for Acute Kidney Injury - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
SP-15016 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
STSE-15 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
THR-184 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
TRC-160334 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Acute Renal Failure (ARF) (Acute Kidney Injury) - Dormant Projects
Acute Renal Failure (ARF) (Acute Kidney Injury) - Discontinued Products
Acute Renal Failure (ARF) (Acute Kidney Injury) - Product Development Milestones
Featured News & Press Releases
Jun 07, 2016: NeuroVive announces CiPRICS study completes enrolment
May 10, 2016: AM-Pharma publishes safety and pharmacokinetic data from Phase I recAP trial
Apr 26, 2016: AM-Pharma receives FDA fast track designation for recAP in Acute Kidney Injury
Mar 14, 2016: NeuroVive announces the CiPRICS study enrols 100 patients and reports favourable safety evaluation
Mar 14, 2016: Quark Pharmaceuticals Doses First Patient In Two Pivotal Clinical Studies of RNAi-Based Therapeutic QPI-1002
Feb 29, 2016: Thrasos Announces Promising Results for Phase II THR-184 Dose Ranging Clinical Study for the Prevention of Acute Kidney Injury (AKI)
Jan 06, 2016: DURECT Announces Positive Phase 1 Data for DUR-928
Dec 14, 2015: NephroGenex Announces FDA Clearance Of IND Application For Clinical Study Of Intravenous Pyridorin In The Treatment Of Acute Kidney Injury
Nov 19, 2015: NeuroVive reports favourable safety evaluation in Phase II acute kidney injury study
Nov 10, 2015: Thrasos Strengthens Composition of Matter Coverage on THR-184 with Japanese Patent Decision
Nov 04, 2015: DiaMedica Provides Corporate Update
Nov 04, 2015: NephroGenex Announces Successful Results from Toxicity Study of Intravenous Pyridorin
Nov 02, 2015: Angion Biomedica to Present Clinical and Preclinical Data at the Upcoming American Society of Nephrology Conference in San Diego
Oct 30, 2015: Licensee's drug to commence Phase 2 and Phase 3 trials
Jul 07, 2015: Thrasos Completes Enrollment of Phase 2 THR-184 Clinical Study for Acute Kidney Injury
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

LIST OF TABLES

Number of Products under Development for Acute Renal Failure (ARF) (Acute Kidney Injury), H2 2016
Number of Products under Development for Acute Renal Failure (ARF) (Acute Kidney Injury) - Comparative Analysis, H2 2016
Number of Products under Development by Companies, H2 2016
Number of Products under Development by Companies, H2 2016 (Contd..1)
Number of Products under Investigation by Universities/Institutes, H2 2016
Comparative Analysis by Late Stage Development, H2 2016
Comparative Analysis by Clinical Stage Development, H2 2016
Comparative Analysis by Early Stage Development, H2 2016
Comparative Analysis by Unknown Stage Development, H2 2016
Products under Development by Companies, H2 2016
Products under Development by Companies, H2 2016 (Contd..1)
Products under Investigation by Universities/Institutes, H2 2016
Acute Renal Failure (ARF) (Acute Kidney Injury) - Pipeline by A1M Pharma AB, H2 2016
Acute Renal Failure (ARF) (Acute Kidney Injury) - Pipeline by Adrenomed AG, H2 2016
Acute Renal Failure (ARF) (Acute Kidney Injury) - Pipeline by Am-Pharma B.V., H2 2016
Acute Renal Failure (ARF) (Acute Kidney Injury) - Pipeline by Angion Biomedica Corp., H2 2016
Acute Renal Failure (ARF) (Acute Kidney Injury) - Pipeline by Atox Bio Ltd., H2 2016
Acute Renal Failure (ARF) (Acute Kidney Injury) - Pipeline by Cellmid Limited, H2 2016
Acute Renal Failure (ARF) (Acute Kidney Injury) - Pipeline by Complexa, Inc., H2 2016
Acute Renal Failure (ARF) (Acute Kidney Injury) - Pipeline by DiaMedica Inc., H2 2016
Acute Renal Failure (ARF) (Acute Kidney Injury) - Pipeline by Digna Biotech, S.L., H2 2016
Acute Renal Failure (ARF) (Acute Kidney Injury) - Pipeline by DURECT Corporation, H2 2016
Acute Renal Failure (ARF) (Acute Kidney Injury) - Pipeline by F. Hoffmann-La Roche Ltd., H2 2016
Acute Renal Failure (ARF) (Acute Kidney Injury) - Pipeline by G1 Therapeutics, Inc., H2 2016
Acute Renal Failure (ARF) (Acute Kidney Injury) - Pipeline by Kringle Pharma, Inc., H2 2016
Acute Renal Failure (ARF) (Acute Kidney Injury) - Pipeline by NephroGenex, Inc., H2 2016
Acute Renal Failure (ARF) (Acute Kidney Injury) - Pipeline by NeuroVive Pharmaceutical AB, H2 2016
Acute Renal Failure (ARF) (Acute Kidney Injury) - Pipeline by Noorik Biopharmaceuticals AG, H2 2016
Acute Renal Failure (ARF) (Acute Kidney Injury) - Pipeline by Noxxon Pharma AG, H2 2016
Acute Renal Failure (ARF) (Acute Kidney Injury) - Pipeline by Orion Oyj, H2 2016
Acute Renal Failure (ARF) (Acute Kidney Injury) - Pipeline by ProMetic Life Sciences Inc., H2 2016
Acute Renal Failure (ARF) (Acute Kidney Injury) - Pipeline by Quark Pharmaceuticals, Inc., H2 2016
Acute Renal Failure (ARF) (Acute Kidney Injury) - Pipeline by SBI Pharmaceuticals Co., Ltd., H2 2016
Acute Renal Failure (ARF) (Acute Kidney Injury) - Pipeline by Spherium Biomed S.L., H2 2016
Acute Renal Failure (ARF) (Acute Kidney Injury) - Pipeline by STATegics, Inc., H2 2016
Acute Renal Failure (ARF) (Acute Kidney Injury) - Pipeline by Stealth BioTherapeutics Inc., H2 2016
Acute Renal Failure (ARF) (Acute Kidney Injury) - Pipeline by Thrasos Therapeutics Inc., H2 2016
Acute Renal Failure (ARF) (Acute Kidney Injury) - Pipeline by Torrent Pharmaceuticals Limited, H2 2016
Assessment by Monotherapy Products, H2 2016
Assessment by Combination Products, H2 2016
Number of Products by Stage and Target, H2 2016
Number of Products by Stage and Mechanism of Action, H2 2016
Number of Products by Stage and Route of Administration, H2 2016
Number of Products by Stage and Molecule Type, H2 2016
Acute Renal Failure (ARF) (Acute Kidney Injury) - Dormant Projects, H2 2016
Acute Renal Failure (ARF) (Acute Kidney Injury) - Discontinued Products, H2 2016

LIST OF FIGURES

Number of Products under Development for Acute Renal Failure (ARF) (Acute Kidney Injury), H2 2016
Number of Products under Development for Acute Renal Failure (ARF) (Acute Kidney Injury) - Comparative Analysis, H2 2016
Number of Products under Development by Companies, H2 2016
Comparative Analysis by Clinical Stage Development, H2 2016
Comparative Analysis by Early Stage Products, H2 2016
Assessment by Monotherapy Products, H2 2016
Number of Products by Top 10 Targets, H2 2016
Number of Products by Stage and Top 10 Targets, H2 2016
Number of Products by Top 10 Mechanism of Actions, H2 2016
Number of Products by Stage and Top 10 Mechanism of Actions, H2 2016
Number of Products by Routes of Administration, H2 2016
Number of Products by Stage and Routes of Administration, H2 2016
Number of Products by Molecule Types, H2 2016
Number of Products by Stage and Molecule Types, H2 2016

COMPANIES MENTIONED

A1M Pharma AB
Adrenomed AG
Am-Pharma B.V.
Angion Biomedica Corp.
Atox Bio Ltd.
Cellmid Limited
Complexa, Inc.
DiaMedica Inc.
Digna Biotech, S.L.
DURECT Corporation
F. Hoffmann-La Roche Ltd.
G1 Therapeutics, Inc.
Kringle Pharma, Inc.
NephroGenex, Inc.
NeuroVive Pharmaceutical AB
Noorik Biopharmaceuticals AG
Noxxon Pharma AG
Orion Oyj
ProMetic Life Sciences Inc.
Quark Pharmaceuticals, Inc.
SBI Pharmaceuticals Co., Ltd.
Spherium Biomed S.L.
STATegics, Inc.
Stealth BioTherapeutics Inc.
Thrasos Therapeutics Inc.
Torrent Pharmaceuticals Limited
Skip to top


Acute Spinal Cord Injury - Pipeline Review, H2 2015 US$ 1,600.00 Aug, 2015 · 52 pages

Ask Your Question

Acute Renal Failure (ARF) (Acute Kidney Injury) - Pipeline Review, H2 2016
Company name*:
Contact person*:
Phone/fax*:
Email*:
Request invoice
Your enquiry:
Please click on a Check Box below to confirm you are not a robot: